Differences in complement activation between complement-resistant and complement-sensitive Moraxella (Branhamella) catarrhalis strains occur at the level of membrane attack complex formation

The mechanism of resistance to human complement-mediated killing in Moraxella catarrhalis was studied by comparing different complement-sensitive and complement-resistant M. catarrhalis strains in a functional bystander hemolysis assay and an enzyme-linked immunosorbent assay (ELISA) for soluble terminal complement complexes. Complement-resistant stains appeared to activate complement to the same extent as, or even slightly better than, complement-sensitive strains. This indicates that complement-resistant strains do not inhibit classical or alternative pathway activation but interfere with complement at the level of membrane attack complex formation. A clear difference in dose-response curves for resistant and sensitive strains was observed both in the bystander hemolysis assay and in the ELISA. Complement-resistant strains showed optimum curves, whereas complement-sensitive strains gave almost linear curves. We conclude that resistant strains bind and/or inactivate one of the terminal complement components or intermediates involved in membrane attack complex formation. Trypsin, known to abolish complement resistance, changed the optimum dose-response curve of a resistant strain to a linear one, which strongly suggests that complement resistance is mediated by an M. catarrhalis-associated protein. This protein acts directly or through the binding of a terminal complement inhibitor present in serum.

[1]  J. Verhoef,et al.  Complement resistance in Branhamella (Moraxella) catarrhalis , 1993, The Lancet.

[2]  B. Pussell,et al.  Vitronectin‐mediated inhibition of complement: evidence for different binding sites for C5b‐7 and C9 , 1993, Clinical and experimental immunology.

[3]  J. Dorca,et al.  Branhamella catarrhalis respiratory infections. , 1992, The European respiratory journal.

[4]  P. Densen.  COMPLEMENT DEFICIENCIES AND MENINGOCOCCAL DISEASE , 1991, Clinical and experimental immunology.

[5]  F. Boyle,et al.  Branhamella (Moraxella) catarrhalis: pathogenic significance respiratory infections , 1991, The Medical journal of Australia.

[6]  J. Griffiss,et al.  Endogenous sialylation of the lipooligosaccharides of Neisseria meningitidis , 1991, Journal of bacteriology.

[7]  B. Catlin.  Branhamella catarrhalis: an organism gaining respect as a pathogen , 1990, Clinical Microbiology Reviews.

[8]  D. Musher,et al.  Interruption of capsule production in Streptococcus pneumonia serotype 3 by insertion of transposon Tn916 , 1990, Infection and immunity.

[9]  S. Berk,et al.  A comparison of serum bactericidal activity and phenotypic characteristics of bacteremic, pneumonia-causing strains, and colonizing strains of Branhamella catarrhalis. , 1990, The American journal of medicine.

[10]  P. Brandtzaeg,et al.  Complement activation and endotoxin levels in systemic meningococcal disease. , 1989, The Journal of infectious diseases.

[11]  P. Densen.  Interaction of complement with Neisseria meningitidis and Neisseria gonorrhoeae , 1989, Clinical Microbiology Reviews.

[12]  P. Rice.  Molecular basis for serum resistance in Neisseria gonorrhoeae , 1989, Clinical Microbiology Reviews.

[13]  A. D'apice,et al.  SP-40,40, a newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits in glomerulonephritis. , 1988, The Journal of clinical investigation.

[14]  S. Frøland,et al.  Quantification of the Terminal Complement Complex in Human Plasma by an Enzyme‐Linked Immunosorbent Assay Based on Monoclonal Antibodies against a Neoantigen of the Complex , 1985, Scandinavian journal of immunology.

[15]  J. Tschopp,et al.  Monoclonal Antibodies Recognizing a Neoantigen of Poly(C9) Detect the Human Terminal Complement Complex in Tissue and Plasma , 1985, Scandinavian journal of immunology.

[16]  D. Musher,et al.  Development of bactericidal antibody during Branhamella catarrhalis infection. , 1985, The Journal of infectious diseases.

[17]  K. Joiner,et al.  Bactericidal but not nonbactericidal C5b-9 is associated with distinctive outer membrane proteins in Neisseria gonorrhoeae. , 1985, Journal of immunology.

[18]  S. Neoh,et al.  A simple one-step procedure for preparation of C1-deficient human serum. , 1984, Journal of immunological methods.

[19]  A. Gee,et al.  Differences in cell-bound C8 sites on chicken erythrocytes measured by their reactivity with guinea pig and human C9. , 1980, Journal of immunology.

[20]  H. Rapp,et al.  CHROMATOGRAPHIC SEPARATION OF THE FIRST COMPONENT OF COMPLEMENT AND ITS ASSAY ON A MOLECULAR BASIS. , 1963, Journal of immunology.

[21]  J. Verhoef,et al.  Observations on constitutional resistance to infection. , 1993, Immunology today.

[22]  J. Verhoef,et al.  Functional microassay of complement activation by pneumococci , 1992 .

[23]  J. Cole,et al.  The serum resistance of gonococci in the majority of urethral exudates is due to sialylated lipopolysaccharide seen as a surface coat. , 1992, FEMS microbiology letters.

[24]  K. Preissner,et al.  Structure and biological role of vitronectin. , 1991, Annual review of cell biology.

[25]  P. Rice.  Molecular Basis forSerumResistance inNeisseria gonorrhoeae , 1989 .

[26]  S. Holm,et al.  Studies on Branhamella Catarrhalis (Neisseria catarrhalis) with special reference to maxillary sinusitis. , 1976, Scandinavian journal of infectious diseases.